Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Hyperuricemia correction in men with metabolic syndrome: Acarbose potential. / Reshetnyak, M. V.; Khirmanov, V. N.; Zybina, N. N.; Frolova, M. Yu.
в: Russian Journal of Cardiology, Том 88, № 2, 01.01.2011, стр. 54-58.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Hyperuricemia correction in men with metabolic syndrome: Acarbose potential
AU - Reshetnyak, M. V.
AU - Khirmanov, V. N.
AU - Zybina, N. N.
AU - Frolova, M. Yu
PY - 2011/1/1
Y1 - 2011/1/1
N2 - The study was aimed at the investigation of “test” (6 days) and longer-term (8 weeks) acarbose treatment effects on plasma uric acid (UA) concentration in patients with metabolic syndrome (MS). Material and methods. In total, 33 men with MS and carbohydrate metabolism disturbances were administered 6-day “test” acarbose therapy. At baseline and 7 days later, saccharose tolerance test was performed, with the measurement of venous plasma levels of fasting UA, fasting fructose, glucose (fasting, 60 and 120 minutes after saccharose load), and insulin (fasting and 120 minutes after the load). 4 weeks later, 20 patients were administered 8-week acarbose therapy, with standard gradual dose increase. At baseline and after the treatment, venous plasma concentrations of UA and fructose were measured. Results. Hyperfructosemia was observed in 100% of the patients, with mean plasma fructose concentration of 0,82±0,97 mmol/l. Hyperuricemia was observed in 51,5% (n=17), with mean plasma UA concentration of 413,2±86,5 mmol/l. Six-week acarbose therapy resulted in a significant decrease of UA levels (p=0,0015) and fructose levels (p=0,049), as well as in postprandial levels of glucose (p=0,03) and insulin (p=0,013). Eight-week acarbose therapy was associated with mean decrease of plasma UA concentration by 5,8% (p=0,04), but no significant changes in fasting plasma levels of fructose (p>0,05).
AB - The study was aimed at the investigation of “test” (6 days) and longer-term (8 weeks) acarbose treatment effects on plasma uric acid (UA) concentration in patients with metabolic syndrome (MS). Material and methods. In total, 33 men with MS and carbohydrate metabolism disturbances were administered 6-day “test” acarbose therapy. At baseline and 7 days later, saccharose tolerance test was performed, with the measurement of venous plasma levels of fasting UA, fasting fructose, glucose (fasting, 60 and 120 minutes after saccharose load), and insulin (fasting and 120 minutes after the load). 4 weeks later, 20 patients were administered 8-week acarbose therapy, with standard gradual dose increase. At baseline and after the treatment, venous plasma concentrations of UA and fructose were measured. Results. Hyperfructosemia was observed in 100% of the patients, with mean plasma fructose concentration of 0,82±0,97 mmol/l. Hyperuricemia was observed in 51,5% (n=17), with mean plasma UA concentration of 413,2±86,5 mmol/l. Six-week acarbose therapy resulted in a significant decrease of UA levels (p=0,0015) and fructose levels (p=0,049), as well as in postprandial levels of glucose (p=0,03) and insulin (p=0,013). Eight-week acarbose therapy was associated with mean decrease of plasma UA concentration by 5,8% (p=0,04), but no significant changes in fasting plasma levels of fructose (p>0,05).
KW - Acarbose
KW - Diabetes mellitus
KW - Fructose
KW - Hyperuricemia
KW - Impaired glucose tolerance
KW - Metabolic syndrome
UR - http://www.scopus.com/inward/record.url?scp=84933041600&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84933041600
VL - 88
SP - 54
EP - 58
JO - РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ
JF - РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ
SN - 1560-4071
IS - 2
ER -
ID: 125110476